Zeenat Parween, Correspondent, India Pharma Outlook
Quality agreements have evolved far beyond legal documentation. In 2026, they serve as critical operational frameworks that define responsibilities, communication expectations, and quality oversight between sponsors and CDMOs.
Weak or generic agreements create dangerous compliance gaps long before manufacturing begins. During deviations, product complaints, or regulatory inspections, unclear responsibilities can quickly escalate into delayed investigations, reporting failures, and operational confusion.
A strong quality agreement clearly defines accountability across all major quality functions, including change control, deviation management, batch release procedures, supplier qualification, documentation review, and regulatory communication. Every agreement should be tailored to the specific manufacturing process, product category, and regulatory market involved.
One of the most important sections within a quality agreement involves change management procedures. Even seemingly minor manufacturing adjustments can create major regulatory implications if sponsors are not informed properly. Changes involving raw material suppliers, analytical methods, equipment, or process parameters may require additional regulatory filings or validation activities.
In 2026, regulators increasingly expect pharmaceutical sponsors to maintain active oversight of outsourced manufacturing operations. Companies can no longer assume that compliance responsibility rests solely with the CDMO. Regulatory agencies continue to emphasize that sponsors remain ultimately accountable for product quality and patient safety.
Effective quality agreements generally define:
Strong agreements also establish expectations during inspection events. Sponsors should know exactly when they will be notified about regulatory findings and how communication will occur throughout the inspection process.
The best CDMO partnerships treat quality agreements as living operational documents rather than static contracts. They are reviewed regularly, updated proactively, and integrated into day-to-day quality management systems.
In highly regulated pharmaceutical environments, inspection readiness cannot be treated as a temporary activity. Leading CDMOs in 2026 operate under the assumption that regulators could arrive at any time.
One of the clearest indicators of this mindset is the strength of the organization’s internal audit program.
Internal audits help identify operational weaknesses before regulators uncover them. Mature CDMOs conduct regular, risk-based audits covering manufacturing operations, laboratories, warehouses, computerized systems, utilities, supplier networks, and quality processes. These audits are designed not only to identify compliance gaps, but also to strengthen continuous improvement efforts across the organization.
Mock inspections have become increasingly common among advanced CDMOs. These exercises simulate real FDA or EMA inspections and test how effectively employees respond under regulatory pressure. Mock audits evaluate documentation accessibility, employee preparedness, interview consistency, and operational discipline.
Elite CDMOs often conduct these exercises using independent third-party experts who can provide objective assessments of inspection readiness.
A proactive audit culture usually reflects strong leadership engagement. Organizations with mature compliance systems typically involve executive management directly in audit reviews, quality metrics, and CAPA oversight. Compliance is treated as a strategic business priority rather than a reactive obligation.
Strong internal audit programs also support operational continuity by identifying risks before they escalate into larger regulatory events. This reduces the likelihood of supply disruptions, delayed approvals, or costly remediation programs.
For pharmaceutical sponsors, partnering with a CDMO that prioritizes continuous inspection readiness significantly lowers long-term operational and regulatory risk.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")